-- Initial experiments demonstrate expeditious
potential for high-volume production of ImmCelz® with consistent
potency --
PHOENIX, April 20,
2022 /PRNewswire/ -- Creative Medical Technology
Holdings, Inc. ("Creative Medical Technology" or the "Company")
(NASDAQ: CELZ), a leading commercial stage biotechnology company
focused on a regenerative approach to immunotherapy, urology,
neurology, and orthopedics, today announced progress in developing
a reproducible clinical grade product of ImmCelz®. Multiple
clinical experiments were performed in which the ImmCelz®
product was produced in less than 72 hours, utilizing the Company's
cell-free supercharging solution. The amount of ImmCelz®
produced was significantly greater than the control in numerous
replicates of the experiments. There was also the ability to verify
repeated potency of the final ImmCelz® product.
Timothy Warbington, President and
CEO of the Company, commented, "We are excited to receive this
great news, which further validates our immunotherapy platform and
sets the stage for advancing clinical studies. We look
forward to continuing to work closely with team members at the
University of Miami who bring decades
of combined experience to our projects. We believe that our
Immcelz® program has enormous potential to improve outcomes
for patients across multiple indications, including stroke, Type I
diabetes, heart disease, liver disease, and kidney disease."
About ImmCelz®
ImmCelz®, which is protected by trade secrets and published U.S.
patents, utilizes adult stem cells derived from qualified donors to
endow specific properties to the patient's immune cells. After
the patient's harvested cells are incubated with the Company's
cell-free reprogramming "cocktail", the cells are re-injected back
into the patient. These "supercharged" cells subsequently
"educate" other cells of the immune system to stop attacking the
body, while preserving the ability to attack foreign pathogens.
The Company plans to advance multiple indications for ImmCelz®
starting with stroke, which is currently under FDA review. Upon
successful approval to proceed with clinical trials for stroke, the
Company anticipates accelerating additional therapies under the
ImmCelz® umbrella, including for Type I diabetes, heart disease,
liver disease, and kidney disease.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage
biotechnology company specializing in stem cell technology in the
fields of immunotherapy, urology, neurology, and orthopedics. For
further information about the Company, please visit
www.creativemedicaltechnology.com.
Forward Looking Statements
This news release may contain forward-looking statements
including but not limited to comments regarding the timing and
content of upcoming clinical trials and laboratory results,
marketing efforts, funding, etc. Forward-looking statements address
future events and conditions and, therefore, involve inherent risks
and uncertainties. Actual results may differ materially from those
currently anticipated in such statements. See the periodic and
other reports filed by Creative Medical Technology Holdings, Inc.
with the Securities and Exchange Commission and available on the
Commission's website at www.sec.gov.
Company
Contact
|
|
Investor
Relations
|
|
|
|
Creative Medical
Technology
|
|
The Equity Group
Inc.
|
IR@CreativeMedicalTechnology.com
|
|
Kalle Ahl,
CFA
|
|
|
|
|
|
(212)
836-9614
|
|
|
kahl@equityny.com
|
|
|
|
|
|
Devin
Sullivan
|
|
|
(212)
836-9608
|
|
|
dsullivan@equityny.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/creative-medical-technology-announces-progress-in-developing-a-reproducible-clinical-grade-of-the-companys-immcelz-product-301528924.html
SOURCE Creative Medical Technology Holdings, Inc.